Inovio Pharmaceuticals, Inc.
INOHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframePart of the healthcare sector, Inovio Pharmaceuticals, Inc. (INO) is listed under Biotechnology. The $147.9M market capitalization puts INO squarely in micro-cap range for its industry. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Market Cap
$147.9M
Beta
1.63
P/E (TTM)
—
P/E (Fwd)
-3.25
EPS (TTM)
$-1.03
EPS (Fwd)
$-0.44
ROE
-409.9%
ROA
-84.2%
Cash
$36.7M
Total Debt
$8.0M
Free CF
-$33.9M
52W Change
-50.2%
Annual Financials
Cash vs Debt
Where INO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, INO finished 5.43% above its 150-day moving average ($1.29) and 5.56% below its 200-day moving average ($1.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INO overbought or oversold?
At the September 3, 2026 close, INO's RSI(14) was 78.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $36.7M in cash and $8.0M in debt, INO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$33.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -409.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $10.3M (2022) to $65K (2025), a 99% decline worth watching.
Inovio Pharmaceuticals, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Inovio Pharmaceuticals, Inc. and its sector.